Head-to-head evidence
amycretin vs MET-233i
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
amycretin
Developed by Novo Nordisk
NCT06064006 · Phase 2 · completed
The study was randomized, quadruple-masked, and placebo-controlled, with 125 participants, providing a meaningful controlled design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
This trial's registered primary endpoint was safety (treatment-emergent adverse events); the figures shown are its prespecified secondary weight-change endpoints as published in The Lancet.
Next expected readout: December 2027 · NCT07587710 (registry estimate)
MET-233i
Developed by Pfizer
NCT07022977 · Phase 1 · completed
Participants were randomly assigned to MET233 or a matching placebo, with everyone blinded to the assignment, which is a sound safety-testing design. However, the trial's main measure was side-effect occurrence rather than weight loss, which was only a secondary measure, and results have not been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amycretin's landscape · MET-233i's landscape